BioLineRx is trading 6.88% down at $2.57 after weak Q2 financial results and financing-related dilution pressure.
- August 31 earnings showed Q2 royalty revenue of $294 thousand; net loss widened to $4.339 million.
- A recently announced $3.75 million offering involving ADSs and warrants creates dilution pressure; GLIX1 development advanced.
- No new BioLineRx announcement dated September 2 was identified. The company-specific decline came despite biotechnology-sector strength; linkage remains unconfirmed, so confidence is medium.